Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

Note: EPS may not be comparable

Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.46), $0.09 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• RBC Capital Starts Enact Holdings Inc (ACT) at Sector Perform